Company profile: Sequella
1.1 - Company Overview
Company description
- Provider of biopharmaceutical products for diagnosing and treating epidemic infectious diseases, including SQ109 (Phase 2 for multidrug-resistant pulmonary tuberculosis), Sutezolid (oxazolidinone in clinical development for tuberculosis), SQ609 (preclinical for tuberculosis), SQ641 (preclinical for C. difficile and nontuberculous mycobacteria), B-SMART rapid TB susceptibility tests, and small-molecule and natural product drug discovery programs.
Products and services
- B-SMART Technology: Sequella architects a licensed technology for developing rapid tuberculosis antimicrobial susceptibility tests, enabling development of rapid TB antimicrobial susceptibility testing
- SQ109: Sequella advances a clinical-stage drug candidate undergoing phase 2 trials for the treatment of multidrug-resistant pulmonary tuberculosis, specifically targeting MDR pulmonary TB
- Sutezolid: Sequella develops an oxazolidinone-class candidate in clinical development for tuberculosis, with exclusive worldwide rights acquired from Pfizer for this TB therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sequella
Meretek Diagnostics
HQ: United States
Website
- Description: Provider of non-invasive, non-radioactive breath tests and instruments for diagnostic applications, offering BreathTek UBT and BreathTek-UBiT collection kits for qualitative detection of urease associated with Helicobacter pylori in the human stomach, supporting initial diagnosis and post-treatment monitoring of Helicobacter pylori infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Meretek Diagnostics company profile →
Altesa BioSciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on accelerating the development of new treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Altesa BioSciences company profile →
Lumen Bioscience
HQ: United States
Website
- Description: Provider of biologic drug and vaccine development and manufacturing, leveraging a platform for rapid, cost-effective production. Pipeline includes biologic cocktails for C. difficile colitis, Covid-19 GI infection, and inflammatory bowel disease, a preclinical cardiometabolic program with Novo Nordisk, and a Phase 2 product candidate for traveler’s diarrhea backed by CARB-X and the Bill & Melinda Gates Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumen Bioscience company profile →
Ibis Biosciences
HQ: United States
Website
- Description: Provider of products for the identification and characterization of infectious agents, including the Ibis T5000 Biosensor System, a hardware platform that identifies biological organisms such as bacteria, viruses, fungi and protozoa and provides information on drug resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ibis Biosciences company profile →
Immtech Pharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics, focusing on the discovery and commercialization of treatments for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immtech Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sequella
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sequella
2.2 - Growth funds investing in similar companies to Sequella
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sequella
4.2 - Public trading comparable groups for Sequella
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →